

BIOCHEMICAL DATA AS IMPORTANT CLUES FOR DIAGNOSIS OF SUCLA2 DEFECTS

Nogueira C¹, Garcia P², Diogo L², Valongo C¹, Santorelli FM³, Vilarinho L¹

¹Genetics Department, R&D Unit, National Institute of Health, INSA, Porto, Portugal; ²Hereditary Metabolic Diseases Unit, Children's Hospital, Coimbra, Portugal; ³Molecular Medicine & Neurogenetics, IRCCS Fondazione Stella Maris, Pisa, Italy

INTRODUCTION

Succinyl CoA synthase is a mitochondrial matrix enzyme that catalyzes the reversible synthesis of succinate and ATP or GTP from succinyl-CoA and ADP in the tricarboxylic acid (TCA) cycle. This enzyme is made up of two subunits, α and β , encoded by *SUCLG1* and *SUCLA2*, respectively (Fig 1) [1].




Figure 1. Relevant metabolic pathways illustrating the metabolic effects of ADP-forming succinyl-CoA synthetase deficiency.

The clinical features of patients with mutations in *SUCLA2* include early childhood hypotonia, developmental delay, and almost invariably, progressive dystonia and sensorineural deafness. Mutations in *SUCLA2* and *SUCLG1* cause an encephalomyopathic form of infantile mtDNA depletion syndrome [2].

A useful diagnostic clue in succinyl CoA synthase disorders is a "mildly" elevated urinary methylmalonic acid (MMA), and presence of TCA intermediates.

To date, few patients with *SUCLG1* mutations have been reported, whereas mutations in *SUCLA2* have been reported in 20 patients [3]. We here present an additional patient with a novel *SUCLA2* mutation.

PATIENTS AND METHODS

We report a 17-month-old-boy, who presented severe muscular hypotonia, failure to thrive, developmental delay, weight loss during a gastroenteritis crises, dysmorphism and muscular atrophy.

A biochemical investigation disclosed hyperlactacidemia together with moderate excretion of MMA and elevated C4-dicarboxylic carnitine (C4DC).

Sequencing analysis of *SUCLA2* and *SUCLG1*, mitochondrial DNA quantification and western blot was performed in patient's fibroblasts, using standard methods.

RESULTS

Mutation analysis of *SUCLA2* revealed a novel homozygous c.985A>G mutation in exon 8 (p.M329V) (Fig 2A). The involvement of *SUCLA2* was confirmed by western blot analysis, which showed some residual amount of *SUCLA2* protein in patient's fibroblasts (Fig 2B). The patient also presented a moderate mitochondrial DNA depletion in fibroblasts (40% of aged-matched controls). This missense mutation affects an amino acid that is highly conserved in different species and was not found in controls. The analysis by bioinformatics tools also confirmed a pathogenic mutation (Fig 3). Altogether, these findings indicate that the identified mutation is pathogenic and responsible for this disorder.




Figure 2. Identification of a novel *SUCLA2* mutation. **A)** Patient's *SUCLA2* sequence with c.985A>G (p.M329V) mutation; **B)** Western-blot analysis of patient's fibroblasts (P) and a control subject (C).




Figure 3. Analysis by bioinformatics tools of *SUCLA2* mutation: p.M329V. **A)** PolyPhen-2 prediction of functional effects of human variations; **B)** ClustalW alignments; **C)** Sift predictions.

DISCUSSION / CONCLUSION

The clinical and biochemical phenotype of our patient is strikingly similar to other reported patients with *SUCLA2* mutations [1]. In addition, the mildly elevated levels of MMA and C4DC raised the suspicion of this disease, which was confirmed by the identification of a novel mutation in *SUCLA2*. In agreement with this results, western blot showed some residual amount of *SUCLA2* protein and a moderate reduction of mitochondrial DNA copy number was found in patient's fibroblasts.

Our study contributed to expand the spectrum of patients with *SUCLA2* mutations, and will be important for an accurate genetic counseling and a prenatal diagnosis to the affected family.

REFERENCES

- [1] Carrozzo R, Dionisi-Vici C, Steuerwald U, Lucioi S, Deodato F, Di Giandomenico S, Bertini E, Franke B, Kluijtmans LA, Meschini MC, Rizzo C, Piemonte F, Rodenburg R, Santer R, Santorelli FM, van Rooij A, Vermunt-de Koning D, Morava E, Wevers RA. *SUCLA2* mutations are associated with mild methylmalonic aciduria, Leigh-like encephalomyopathy, dystonia and deafness. *Brain*. 2007; 130(Pt 3):862-74.
- [2] Elpeleg O, Miller C, Hershkovitz E, Bitner-Glindzic M, Bondi-Rubinstein G, Rahman S, et al. Deficiency of the ADP-forming succinyl-CoA synthase activity is associated with encephalomyopathy and mitochondrial DNA depletion. *Am J Hum Genet* 2005; 76: 1081-6.
- [3] El-Hattab AW, Scaglia F. Mitochondrial DNA depletion syndromes: review and updates of genetic basis, manifestations, and therapeutic options. *Neurotherapeutics*. 2013; 10(2):186-98.